An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
Clinical trial NCT00216697 · COMPLETED
Trial details
- NCT number
- NCT00216697
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-03-01
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.